-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: rare diseases
Mito What???
Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, mitochondrial disease was virtually unheard of. Just 10 years ago, it was considered rare. Today, according to NORD, a disease is considered rare when less than 200,000 people are affected. Mitochondrial disease is not a single disease, but rather an entire umbrella of rare diseases. For example, Alpers disease and Barth syndrome are very different and rare forms of mitochondrial Read More >
Health
Leave a comment
Email This Post
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Rare Disease Day 2014: Joining Together for Better Care
There are more than 6,000 different rare diseases affecting over 60 million people across Europe and North America, alone, and millions more throughout the world. Most of these diseases are genetic, serious, chronic and debilitating. Each disease is different, but they affect people in similar ways. Joining together can help patients and their families find common solutions for care and remind them they are not alone. As the world marks Rare Disease Day on February Read More >
The Ethics of the Market Access Debate
At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >
A Bright Future for Orphan Disease Indications
In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals). Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >
Navigating the Rare Disease World
The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled by the entrance of big pharmaceutical companies and U.S. legislation favoring development and coverage. This growth promises to improve the health of patients with debilitating and life-threatening disorders. Hoping to further the rare disease dialogue and relationship building opportunities, the 2013 Orphan Disease Forum will provide unique perspective on the orphan drug marketplace, regulatory considerations and much more. Operating within Read More >
